Krueger v. Wyeth, Inc.
Overview
Krueger v. Wyeth, Inc. (U.S. District Court for the Southern District of California, November 12, 2020): A California federal court granted a distribution of Class Settlement funds in a case alleging that Wyeth Pharmaceuticals violated California consumer protection laws via long-term, widespread marketing campaigns intended to misrepresent risks and benefits associated with the company’s hormone replacement therapy (HRT) drugs. April Krueger brought this class action alleging that Wyeth Pharmaceuticals misrepresented that its HRT drugs lowered cardiovascular, Alzheimer’s and/or dementia risk, and did not increase the risk of breast cancer. Because of the suit’s central allegations, the court reasoned that a preference would be given for distributing any excess funds to major California medical centers or targeted research groups that specialized in the prevention, detection, and treatment of breast cancer, cardiac issues, Alzheimer’s, and early-onset dementia, especially for the treatment of women in California communities historically lacking treatment. Read the decision here.
View all cases in the Judicial Trends in Public Health – January 15, 2021.